LabGenomics hospital solution team representatives are explaining the NGS-based companion diagnostic service for non-small cell lung cancer at the Lung Cancer Society conference. Provided by LabGenomics
LabGenomics announced on the 11th that it attended the Korean Association for Lung Cancer (KALC) International Conference (IC) held at Lotte Hotel World for two days starting from the 7th.
The event was hosted by the Korean Association for Lung Cancer, with global companies such as Merck, AstraZeneca, Roche, and leading medical scholars from around the world participating. LabGenomics introduced a variety of NGS cancer test portfolios necessary for next-generation sequencing (NGS)-based solid and hematologic cancer reimbursed tests, including ▲OTD Liquid (solid cancer liquid biopsy service) and ▲OTD Lung (companion diagnostic service for non-small cell lung cancer). In particular, OTD Lung, a companion diagnostic test targeting non-small cell lung cancer (NSCLC), attracted attention.
A representative from LabGenomics’ Hospital Solutions Team stated, “Lung cancer progresses rapidly due to tissue characteristics and cancer types, requiring prompt testing, but it is difficult to obtain tissue samples,” adding, “We will provide fast and efficient testing solutions under the concept of ‘half the specimen, half the turnaround time (TAT)’ for targeted treatment of lung cancer patients.”
They continued, “NGS technology is becoming an essential test for realizing precision medicine, and there was a high level of interest in our testing services,” and “Due to reduced patient burden under selective reimbursement criteria, inquiries have been increasing from tertiary hospitals and cancer specialty hospitals.” Their strategy is to provide diagnostic data that can increase the possibility of prescribing targeted therapies tailored to gene mutations in NSCLC patients, thereby improving patients’ treatment outcomes.
The OTD Liquid test, a solid cancer liquid biopsy test using IMBDx’s AlphaLiquid100 panel, also received attention at the conference. OTD Liquid analyzes gene mutations from the patient’s blood, enabling personalized treatment options based on genetic changes even when tissue biopsy is not possible.
Earlier, in September, the Korean Society of Medical Oncology and the Korean Society of Pathologists recommended NGS-based gene panel testing for patients with advanced and metastatic solid cancers through the ‘Precision Medicine Guidelines.’ NGS was designated as a conditional selective reimbursement item with a 50% coverage rate in 2017, but last December, the patient co-payment rate for NGS selective reimbursement was increased from 50% to 80% for cancers other than lung cancer.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
